• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Revenue from new cancer-drugs substantially greater than cost of development

byJames EnglandandAnees Daud
September 20, 2017
in Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The cost of research and development (R&D) for a company to develop their first FDA approved cancer medication is estimated to be $648.0 million, while revenue was substantially greater despite relatively short time on the market.

2. In-house preclinical development and first-in-class medications required greater research and development cost.

Evidence Rating Level: 3 (Average)

Study Rundown: The rising cost of cancer therapeutics has become a notable point of controversy with cost of new cancer drugs routinely exceed $100,000/year primarily driven by prices set by pharmaceutical companies. The prices of medications have been justified due to the substantial cost of development for a single therapeutic agent and relatively small target populations. Estimates of R&D cost have varied widely based on source of data and are often complicated by the difficulty attributing cost of drug development attempts that never obtain FDA approval. The current study focused solely on companies that developed one FDA approved medication for cancer therapy and used securities and exchange commission (SEC) filings to estimate total R&D costs including failed drug development attempts. The study found that for 10 companies, the development of one FDA-approved drug had a median cost of $648.0 million but median revenue of $1658.4 million after a median of 4 year on market. In-house preclinical development and first-in-class medications were shown to have increased R&D cost.

The study provides useful estimates for the development of cancer therapeutics that can help inform policy makers with regards to possible regulation of drug costs. The main advantage of this analysis is the focus on companies that have developed one FDA approved drug; thereby attributing all cost and revenue for a single successful drug. The main limitations of the analysis include the reliance on secondhand SEC data for analysis. The focus on companies that have developed a successful drug eliminate the companies that failed to successfully obtain FDA approval from cost and risk estimates. Finally, the study is not generalizable to medications used for non-oncologic purposes which may have different cost and revenue potentials.

Click to read the study, published in JAMA Internal Medicine

Relevant Reading: The $2.6 Billion Pill — Methodologic and Policy Considerations

RELATED REPORTS

#VisualAbstract High cost of healthcare was the highest patient-reported barrier to accessing outpatient dermatologic care

#VisualAbstract A multimodal intervention reduced peripheral intravenous catheter failures in hospitalized patients

Higher hospitalist continuity of care linked to improved clinical outcomes

In-Depth [retrospective cohort]: This study included all companies that developed their first FDA-approved medication from January 1, 2006 to December 31, 2015 if that medication was for an oncologic indication. R&D cost was estimated using publically available data from SEC 10 K filings and included the time from the first year of R&D spending to data of FDA approval. Companies were excluded if data for R&D cost were not available.

A total of 13 companies received first FDA drug approval during the study period, with 10 having R&D spending data available through the SEC. The median number of drugs in development for 1 approval was 3.5, with median time of development of 7.3 years. The median cost of drug development was $648.0 million (range, $157.3 million to $1950.8 million), and significantly greater for first in class medications ($899.2 million [range, $328.1 million to $1950.8 million] vs $473.3 million [range, $157.3 million to $815.8 million]; p = 0.047) and self-originated drugs (median, $899.2 million [range, $480.1 million to $1950.8million] vs $328.1 million (range, $157.3million to$815.8 million]; p = 0.02). Total cost for development of the 10 drugs was $9 billion, while total revenue after median 4 years on market was $67 billion.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: healthcare costspharmaceutical
Previous Post

Emergency Departments more likely to transfer injured children on Medicaid

Next Post

Gun laws that require domestic abusers to surrender firearms could save lives

RelatedReports

#VisualAbstract High cost of healthcare was the highest patient-reported barrier to accessing outpatient dermatologic care
StudyGraphics

#VisualAbstract High cost of healthcare was the highest patient-reported barrier to accessing outpatient dermatologic care

November 27, 2021
#VisualAbstract A multimodal intervention reduced peripheral intravenous catheter failures in hospitalized patients
StudyGraphics

#VisualAbstract A multimodal intervention reduced peripheral intravenous catheter failures in hospitalized patients

September 9, 2021
Public Health

Higher hospitalist continuity of care linked to improved clinical outcomes

December 19, 2019
Eating in the absence of hunger linked to toddler obesity
Pediatrics

Significant unreimbursed costs linked to care coordination for medically complex children

December 24, 2018
Next Post
AAP supports mindfulness of children’s media consumption

Gun laws that require domestic abusers to surrender firearms could save lives

PTSD symptoms in Boston-area youth after marathon bombing

Risk of death and cardiac arrest during triathlon may be higher in older males

Rapid genetic testing useful for diagnosis of critically ill children

Rapid genetic testing useful for diagnosis of critically ill children

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Subthreshold micropulse laser is equivalent to standard laser for treating diabetic macular edema
  • Gadolinium-containing contrast associated with nephrogenic fibrosing dermopathy and systemic fibrosis [Classics Series]
  • Study supports continued use of amoxicillin as first-line therapy for pediatric ear infections
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.